Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
Royalty Pharma (NASDAQ:RPRX) has appointed two new independent directors to its Board: Carole Ho, Chief Medical Officer at Denali Therapeutics, and Elizabeth Weatherman, Special Limited Partner at Warburg Pincus. The appointments increase independent board representation to over 90% and follow the company's acquisition of its external manager.
Dr. Ho brings 20 years of biopharma experience, currently leading therapeutic development at Denali and previously serving as Vice President of Clinical Development at Genentech. Weatherman contributes 35 years of healthcare industry investment expertise from her tenure at Warburg Pincus, where she led the Healthcare Group and served on numerous corporate boards.
Royalty Pharma (NASDAQ:RPRX) ha nominato due nuovi direttori indipendenti nel suo Consiglio di Amministrazione: Carole Ho, Chief Medical Officer di Denali Therapeutics, e Elizabeth Weatherman, Special Limited Partner presso Warburg Pincus. Queste nomine portano la rappresentanza indipendente nel consiglio a oltre il 90% e seguono l'acquisizione da parte dell'azienda del suo gestore esterno.
La Dott.ssa Ho vanta 20 anni di esperienza nel settore biofarmaceutico, attualmente guida lo sviluppo terapeutico in Denali e in precedenza è stata Vicepresidente dello Sviluppo Clinico presso Genentech. Weatherman apporta 35 anni di esperienza negli investimenti nel settore sanitario, maturata durante il suo periodo in Warburg Pincus, dove ha guidato il Gruppo Healthcare e fatto parte di numerosi consigli aziendali.
Royalty Pharma (NASDAQ:RPRX) ha nombrado a dos nuevos directores independientes en su Junta Directiva: Carole Ho, Chief Medical Officer en Denali Therapeutics, y Elizabeth Weatherman, Socia Limitada Especial en Warburg Pincus. Estas incorporaciones elevan la representación independiente en el consejo a más del 90% y se producen tras la adquisición por parte de la empresa de su gestor externo.
La Dra. Ho aporta 20 años de experiencia en biofarmacéutica, liderando actualmente el desarrollo terapéutico en Denali y habiendo sido previamente Vicepresidenta de Desarrollo Clínico en Genentech. Weatherman suma 35 años de experiencia en inversiones en la industria sanitaria, adquirida durante su etapa en Warburg Pincus, donde dirigió el Grupo de Salud y formó parte de numerosos consejos corporativos.
Royalty Pharma (NASDAQ:RPRX)는 이사회에 두 명의 새로운 독립 이사를 임명했습니다: Carole Ho, Denali Therapeutics의 최고 의료 책임자, 그리고 Elizabeth Weatherman, Warburg Pincus의 특별 유한 파트너. 이번 임명으로 독립 이사 비율이 90% 이상으로 증가했으며, 이는 회사가 외부 매니저를 인수한 데 따른 조치입니다.
Ho 박사는 바이오제약 분야에서 20년의 경력을 보유하고 있으며, 현재 Denali에서 치료제 개발을 이끌고 있고 이전에는 Genentech에서 임상 개발 부사장을 역임했습니다. Weatherman은 Warburg Pincus에서 헬스케어 그룹을 이끌고 수많은 기업 이사회에 참여하며 쌓은 35년의 헬스케어 투자 경험을 제공합니다.
Royalty Pharma (NASDAQ:RPRX) a nommé deux nouveaux administrateurs indépendants à son conseil d'administration : Carole Ho, Chief Medical Officer chez Denali Therapeutics, et Elizabeth Weatherman, associée limitée spéciale chez Warburg Pincus. Ces nominations portent la représentation indépendante au conseil à plus de 90% et font suite à l'acquisition par la société de son gestionnaire externe.
Dr Ho apporte 20 ans d'expérience dans le secteur biopharmaceutique, dirigeant actuellement le développement thérapeutique chez Denali et ayant précédemment occupé le poste de vice-présidente du développement clinique chez Genentech. Weatherman apporte 35 ans d'expertise en investissement dans le secteur de la santé, acquise lors de son passage chez Warburg Pincus, où elle a dirigé le groupe Santé et siégé à de nombreux conseils d'administration.
Royalty Pharma (NASDAQ:RPRX) hat zwei neue unabhängige Direktoren in seinen Vorstand berufen: Carole Ho, Chief Medical Officer bei Denali Therapeutics, und Elizabeth Weatherman, Special Limited Partner bei Warburg Pincus. Mit diesen Ernennungen steigt der Anteil der unabhängigen Vorstandsmitglieder auf über 90% und folgt auf die Übernahme des externen Managers durch das Unternehmen.
Dr. Ho bringt 20 Jahre Erfahrung in der Biopharma-Branche mit, leitet derzeit die therapeutische Entwicklung bei Denali und war zuvor Vice President für klinische Entwicklung bei Genentech. Weatherman verfügt über 35 Jahre Investmenterfahrung im Gesundheitswesen, die sie während ihrer Zeit bei Warburg Pincus gesammelt hat, wo sie die Healthcare-Gruppe leitete und in zahlreichen Unternehmensvorständen tätig war.
- Increased board independence to over 90%, enhancing corporate governance
- Addition of extensive biopharma expertise through Dr. Ho's 20 years of therapeutic development experience
- Strengthened financial oversight with Weatherman's 35 years of healthcare investment expertise
- None.
- Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than
90% - Underscores Royalty Pharma’s commitment to enhanced corporate governance following acquisition of its external manager
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing.
“We are delighted to welcome Carole and Bess to our board,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Their exceptional leadership and passion for innovation will be invaluable as we execute on our long-term strategy. With decades of experience spanning the biopharmaceutical and finance industry, they bring unique insights that will strengthen our board and support our continued growth.”
Carole Ho has 20 years of experience in biopharma. She currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics, where she heads therapeutic development from early-stage planning to late-stage development in rare disease and neurology. Since 2018, she has also served on non-profit, private and public boards. Prior to Denali, she was Vice President of Clinical Development at Genentech, where she led development of therapeutics in neurology, immunology, ophthalmology and infectious disease. Carole received a SB in biochemistry, magna cum laude, from Harvard University and earned her MD, with honors in research, from Weill Cornell Medicine.
Bess Weatherman is a seasoned investor of 35 years across the healthcare industry. She currently serves as a Special Limited Partner at Warburg Pincus, which she joined in 1988. During her tenure, she held the role of Partner, was a member of the Executive Management Group and led the firm’s Healthcare Group. She has served on the boards of numerous public and private companies and brings a deep understanding of capital markets, corporate governance, and medical innovation. Bess received a BA in English, summa cum laude and Phi Beta Kappa, from Mount Holyoke College and earned her MBA from the Stanford Graduate School of Business.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
Who are the new board members appointed to Royalty Pharma (RPRX)?
What is Carole Ho's experience in the pharmaceutical industry?
What percentage of Royalty Pharma's board is now independent?
What is Elizabeth Weatherman's background in healthcare investing?
